Comprehensive studies of changes in the resident intestinal microbiota,
host metabolism and
immune system
reactivity in T1D patients and cohorts at risk of T1D, as well as the correlation with clinical data, anti-islet antigen antibodies and HLA genotypes will enable identification of novel biomarkers and biosignatures, and insights into the pathophysiology of the onset of T1D.